Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is expected to report second quarter earnings results, after market close, on Monday 10th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.32 per share.
Looking ahead, the full year loss are expected at $ 1.36 per share on the revenues of $ 4.06 million.
Previous Quarter Performance
Spectrum Pharmaceuticals, Inc. posted loss for the first quarter of $ 0.36 per share, from the revenue of . The quarterly earnings while revenues compared with the same quarter last year.
Wall street analysts are predicting, SPPI to report 1Q20 loss of $ 0.35 per share from revenue of $ 0.06 million. The bottom line results missed street analysts by $ 0.01 or 2.86 percent, at the same time, top line results analysts by $ 67.77 million or .
Stock Performance
According to the previous trading day, closing price of SPPI was $ 3.85, representing a 121.26 % increase from the 52 week low of $ 1.74 and a 63.58 % decrease over the 52 week high of $ 10.57.
The company has a market capital of $ 546.32 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”SPPI” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Spectrum Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.sppirx.com
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkins lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients.
